Navigation Links
Pharmos Corporation Reports 2009 Third Quarter Results
Date:11/12/2009

urred during the first nine months of 2009 in connection with the trial, comprising CRO-related activities. All patients in the trial completed treatment in July of 2009 and top line clinical data was released in September 2009. The results of the Dextofisopam Phase 2b clinical trial were announced on September 14, 2009. While the trial did not meet the primary endpoints for any of the three drug dose arms, drug activity was clearly evident at the 200 mg. dose level. On October 21, 2009 the Company announced that it had engaged Cowen and Company as advisors to assist with accelerating a partnership arrangement for Dextofisopam.

In process research and development costs which were related to the Vela milestone increased by $1,180,000 from $0 in 2008 to $1,180,000 in 2009. On April 9, 2009 the last patients were enrolled in the Phase 2b trial thus triggering the following milestone: $1 million cash + 2 million shares of Pharmos common stock: Final patient enrolled in Phase 2b trial. The expense of the milestone of $1,180,000 has been reflected in the 1Q 2009 results. The payment of the cash portion of the milestone has been deferred under an amendment to the acquisition agreement. Under the terms of the Vela acquisition agreement as amended, the 2 million shares will be issued on November 2, 2009. Since the trial results were not successful, no other milestones have been achieved.

General and administrative expenses for the first nine months of 2009 decreased by $585,882, or 35%, from $1,687,747 in 2008 to $1,101,865 in 2009. The decline reflects decreases in virtually every general and administrative expense category. The primary reductions include a $359,000 reduction in payroll, a $100,000 reduction in miscellaneous expenses, a $123,000 reduction in consultant and professional fees and a reduction in various other expenses of $75,000. This is offset in part, by increases of $36,000 in investor relations and $34,000 of miscellaneous expenses.
'/>"/>

SOURCE Pharmos Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Pharmos Issues Business Update on Dextofisopam Trial and Financing
2. Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream
3. MedCath Corporation Reports Fourth Quarter Earnings
4. Webcast Alert: Isis Pharmaceuticals and Genzyme Corporation to Present Mipomersen Phase 3 Data in HoFH During AHA
5. Dr. John Mills and Joseph Gentile Join Board of Directors of ChanTest Corporation
6. Volcano Corporation Presentation at Canaccord Adams Conference to Be Webcast
7. Raptor Pharmaceutical Corporation Announces Presentation of Data for NGX426, a Novel, Non-Opioid Oral Analgesic, at Neuropathic Pain Conference
8. China National Medicines Corporation Issues Milestone Purchase Order for 12,000 STA Systems
9. China Medicine Corporation to Acquire Pharmaceutical Manufacturer in Guangzhou
10. MedCath Corporation to Hold Conference Call on Fourth Quarter Results
11. DURECT Corporation Invites You to Join its Third Quarter 2009 Earnings Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... EASTON, Mass. , Sept. 19, 2014 /PRNewswire/ ... "Company") today announced it has received and approved ... Barozyme HT48 instruments and has begun to manufacture ... the first instrument will be ready for shipment ... be built and released at a rate of ...
(Date:9/19/2014)... -- Aufgrund der enormen Nachfrage seines ... aktualisiert, der jetzt auch die Jahre 2014 - ... pharmaserialisation.com , zeigt die Serialisierungsanforderungen weltweit und den ... Für international tätige Unternehmen geht es ... sondern darum, "wann" sie die neu in Kraft ...
(Date:9/19/2014)... CAMBRIDGE, Mass. , Sept. 19, 2014   ... of advanced cancer genome analysis and testing services, ... discovering and developing highly selective kinase inhibitors for ... genomic study of malignant mixed Mullerian tumors (MMMT), ... reproductive system, also known as carcinosarcoma. The new ...
Breaking Medicine Technology:Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 2Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 3Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 2First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 3First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 4
(Date:9/20/2014)... The excitement is building up once again for the annual ... year the Surry Arts Council will be celebrating its 25th year ... are still fans of the Andy Griffith Show. ... CBS from 1960 through 1968. The show ranked by TV ... Mount Airy, North Carolina is where the show was filmed calling ...
(Date:9/20/2014)... September 20, 2014 Plumbing construction ... out of 5, indicating a moderately favorable purchasing environment ... score reflects current and future pricing trends that will ... prices. Other factors that negatively affect buyer power are ... construction and the moderate switching costs. Buyers benefit, however, ...
(Date:9/20/2014)... 2014 Final Cut Pro X Plugin ... of the Information theme for FCPX filmmakers. , “Fun, cool, ... the Information theme,” says Christina Austin, CEO of Pixel Film ... professional.” , Information features easy to use controls that give ... environment. Change the background color, color of each circle outline, ...
(Date:9/20/2014)... 20, 2014 MarijuanaDoctors.com recently returned ... at the PAIN Week conference that was held ... Casino in Las Vegas from September 2nd to ... PAIN Week in the hopes of educating physicians ... and legitimate tool to treat chronic Pain, MarijuanaDoctors.com ...
(Date:9/19/2014)... September 19, 2014 “Copay coupons,” a ... of brand drugs among patients with prescription drug coverage, ... to a new report from the Department of ... (OIG). Federal anti-kickback laws prohibit suppliers from offering side-payments ... the federal government. , The report highlights that two ...
Breaking Medicine News(10 mins):Health News:Mayberry Days Parade Cars will be Provided by Mount Airy Toyota and Mount Airy Chrysler Dodge Jeep Ram 2Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 2Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 3Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 4Health News:Today Pixel Film Studios Announced the Release of the Information Theme for Final Cut Pro X 2Health News:MarijuanaDoctors.com Experiences Unprecedented Support and Growth at Pain Week 2014 2Health News:PCMA: New OIG Report Cites Drug Manufacturer“Copay Coupon” Use in Medicare Part D 2
... well-proven medications, could have huge impact, expert says , ... of a statin and a blood pressure-lowering ACE inhibitor ... or stroke reduced their incidence by more than 60 ... the study all had diabetes or a history of ...
... BNVI ) today announced that it has entered into agreements ... price per unit of $6.20 for aggregate gross proceeds of up ... common stock and ten warrants. Each warrant entitles its holder ... price of $0.85. The warrants may be exercised at any ...
... Anterior cruciate ligament (ACL) injuries are one of the ... of patients undergo reconstructive surgery to repair these injuries. ... issue of The Journal of Bone and Joint Surgery ... increasing substantially and women and younger patients are more likely ...
... have demonstrated that a protein called NEDD9 may be required ... to grow. Their findings, based on the study of a ... issue of Cancer Research , available on-line now. ... evidence that directly demonstrates reduced levels of NEDD9 in a ...
... No clear evidence found that Chantix has dangerous side ... News) -- The smoking cessation drug varenicline (Chantix) does ... to a new British study. , In July, the ... carry a "black-box warning" on its packaging, indicating that ...
... iMobile® Care ... ... information to provide essential and practical aid and care during serious situations is crucial and ... able to deliver a timely response, or to administer self-care without a costly physician or ...
Cached Medicine News:Health News:Drug Combo May Prevent Heart Attacks, Strokes 2Health News:Drug Combo May Prevent Heart Attacks, Strokes 3Health News:Bionovo Announces Pricing of Securities Offering 2Health News:Bionovo Announces Pricing of Securities Offering 3Health News:Teenagers and ACL: Tears common and additional surgery likely 2Health News:NEDD9 protein supports growth of aggressive breast cancer 2Health News:Study Counters Warnings on Quit-Smoking Drug 2Health News:VisionSync Launches a Smart iPhone First Aid App, iMobile Care 2Health News:VisionSync Launches a Smart iPhone First Aid App, iMobile Care 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: